Proscia announced the latest release of Concentriq, the company’s digital pathology platform. New features include a performance analytics module alongside a new suite of automation features. In combination, these capabilities give laboratory managers and operators the critical functionality and insights they need to meaningfully improve productivity while continuously driving quality.
Today’s labs face increasing pressure to drive margins especially in light of decreasing reimbursements. Yet, despite widespread digital transformation of many aspects of the healthcare industry, pathology labs have remained dependent on manual, time-consuming processes to track key business metrics. This has kept labs from improving productivity and making informed decisions that could otherwise improve the bottom line.
“To gain meaningful operational improvements, laboratories must go beyond simply digitizing glass slides,” explains David West, CEO of Proscia. “The introduction of a digital platform that improves efficiency across all aspects of lab operations gives lab owners and managers a way to prosper even as economic pressures intensify. Concentriq improves efficiency, productivity, and profitability in a way that now makes adoption of digital pathology a business imperative.”
The new release extends Concentriq’s image and workflow management functions for efficiency gains and also provides lab managers and administrators the tools they need to make data-driven decisions that continuously improve pathology workflows. New feature descriptions are detailed in "Digital Pathology Benefits Go Beyond the Pathologist: Concentriq Functionality Lab Managers will Love.” Highlights include:
For more information go to https://proscia.com/
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.